Literature DB >> 18332674

Developmental effects of 3,4-methylenedioxymethamphetamine: a review.

Matthew R Skelton1, Michael T Williams, Charles V Vorhees.   

Abstract

+/-3,4-Methylenedioxymethamphetamine (MDMA) is a chemical derivative of amphetamine that has become a popular drug of abuse and has been shown to deplete serotonin in the brains of users and animals exposed to it. To date, most studies have investigated the effects of MDMA on adult animals. With a majority of users of MDMA being young adults, the chances of the users becoming pregnant and exposing the fetuses to MDMA are also a concern. Evidence to date has shown that developmental exposure to MDMA results in learning and memory impairments in the Morris water maze, a task known to be sensitive to hippocampal disruption, when the animals are tested as adults. Developmental MDMA exposure leads to hypoactivity in the offspring as adults but does not affect outcome on tests of anxiety. MDMA administration decreases pup weight, increases corticosterone and brain-derived neurotrophic factor levels during treatment while decreasing brain levels of serotonin; a decrease that initially dissipates and then reappears in adulthood. Neonatal MDMA exposure increases the sensitivity of the serotonin 1A receptor, a possible mechanism underlying the learning and memory deficits seen. Taken together, the evidence shows that MDMA exposure has adverse effects on the developing brain and behavior. The animal and human data on developmental MDMA exposure are reviewed and their public health implications discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332674      PMCID: PMC2888321          DOI: 10.1097/FBP.0b013e3282f62c76

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  137 in total

1.  A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration.

Authors:  M Shankaran; G A Gudelsky
Journal:  Psychopharmacology (Berl)       Date:  1999-11       Impact factor: 4.530

Review 2.  MDMA use and neurocognition: a meta-analytic review.

Authors:  Ari D Kalechstein; Richard De La Garza; James J Mahoney; William E Fantegrossi; Thomas F Newton
Journal:  Psychopharmacology (Berl)       Date:  2006-11-03       Impact factor: 4.530

3.  3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat.

Authors:  Sunila G Nair; Gary A Gudelsky
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

4.  A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy.

Authors:  M I Colado; E O'Shea; R Granados; A Misra; T K Murray; A R Green
Journal:  Br J Pharmacol       Date:  1997-06       Impact factor: 8.739

5.  Treatment with MDMA from P11-20 disrupts spatial learning and path integration learning in adolescent rats but only spatial learning in older rats.

Authors:  Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

6.  Molecular cloning and expression of brain-derived neurotrophic factor.

Authors:  J Leibrock; F Lottspeich; A Hohn; M Hofer; B Hengerer; P Masiakowski; H Thoenen; Y A Barde
Journal:  Nature       Date:  1989-09-14       Impact factor: 49.962

7.  Effects of ecstasy on aldosterone secretion in the rat in vivo and in vitro.

Authors:  N Burns; H J Olverman; P A Kelly; B C Williams
Journal:  Endocr Res       Date:  1996-11       Impact factor: 1.720

8.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain.

Authors:  D L Commins; G Vosmer; R M Virus; W L Woolverton; C R Schuster; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

9.  Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine.

Authors:  J F Nash; H Y Meltzer; G A Gudelsky
Journal:  J Pharmacol Exp Ther       Date:  1988-06       Impact factor: 4.030

10.  Web-based method for translating neurodevelopment from laboratory species to humans.

Authors:  Barbara Clancy; Brandon Kersh; James Hyde; Richard B Darlington; K J S Anand; Barbara L Finlay
Journal:  Neuroinformatics       Date:  2007
View more
  25 in total

Review 1.  Drugs, biogenic amine targets and the developing brain.

Authors:  Aliya L Frederick; Gregg D Stanwood
Journal:  Dev Neurosci       Date:  2009-04-17       Impact factor: 2.984

Review 2.  Neuroimaging of children following prenatal drug exposure.

Authors:  Chris Derauf; Minal Kekatpure; Nurunisa Neyzi; Barry Lester; Barry Kosofsky
Journal:  Semin Cell Dev Biol       Date:  2009-03-13       Impact factor: 7.727

3.  Distinct periods of developmental sensitivity to the effects of 3,4-(±)-methylenedioxymethamphetamine (MDMA) on behaviour and monoamines in rats.

Authors:  Matthew R Skelton; Devon L Graham; Tori L Schaefer; Curtis E Grace; Amanda A Braun; Lindsey N Burns; Robyn M Amos-Kroohs; Michael T Williams; Charles V Vorhees
Journal:  Int J Neuropsychopharmacol       Date:  2011-06-28       Impact factor: 5.176

4.  Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy.

Authors:  Lynn T Singer; Derek G Moore; Sarah Fulton; Julia Goodwin; John J D Turner; Meeyoung O Min; Andrew C Parrott
Journal:  Neurotoxicol Teratol       Date:  2012-03-03       Impact factor: 3.763

Review 5.  Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine.

Authors:  Luke A Downey; Jennifer M Loftis
Journal:  Eur J Pharmacol       Date:  2014-01-28       Impact factor: 4.432

6.  Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.

Authors:  John J D Turner; Andrew C Parrott; Julia Goodwin; Derek G Moore; Sarah Fulton; Meeyoung O Min; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2013-12-10       Impact factor: 4.153

7.  Illicit drug use in late pregnancy associated with stillbirth and eclampsia.

Authors:  Katherine Scott; Narelle Fagermo; Leonie Callaway; Karin Lust
Journal:  Obstet Med       Date:  2010-09-17

8.  One-year outcomes of prenatal exposure to MDMA and other recreational drugs.

Authors:  Lynn T Singer; Derek G Moore; Meeyoung O Min; Julia Goodwin; John J D Turner; Sarah Fulton; Andrew C Parrott
Journal:  Pediatrics       Date:  2012-08-20       Impact factor: 7.124

Review 9.  A structured review of reasons for ecstasy use and related behaviours: pointers for future research.

Authors:  Gjalt-Jorn Ygram Peters; Gerjo Kok
Journal:  BMC Public Health       Date:  2009-07-13       Impact factor: 3.295

10.  During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study.

Authors:  Derek G Moore; John D Turner; Andrew C Parrott; Julia E Goodwin; Sarah E Fulton; Meeyoung O Min; Helen C Fox; Fleur M B Braddick; Emma L Axelsson; Stephanie Lynch; Helena Ribeiro; Caroline J Frostick; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2009-11-25       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.